Daiichi Sankyo and AstraZeneca saw a dip in stock prices after announcing that their Phase III TROPION-Breast01 trial for ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

Key updates in the health sector have emerged, with AstraZeneca facing disappointment in a breast cancer drug trial. The ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

European stock markets rallied on Monday afternoon to finish with moderate gains as dismal economic data increased hopes that ...